Tom Boyles to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications Tom Boyles has written about Antiretroviral Therapy, Highly Active.
Connection Strength
0,134
-
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019 07; 6(7):e428-e437.
Score: 0,134